gdc
FDA NewsLiver CancerNewsworthy

Lenvima a New Option Approved for Initial Treatment of Liver Cancer

October 2018 Vol 4 No 5

In August 2018, the FDA approved Lenvima (lenvatinib; from Eisai) as the first treatment for patients with unresectable hepatocellular carcinoma, or liver cancer. Lenvima was previously approved for thyroid cancer and for kidney cancer.

This new approval was based on a clinical trial of 954 patients with untreated metastatic or unresectable liver cancer, which showed that those who received Lenvima had on average double the time (7.3 months versus 3.6 months) without disease progression than those who received Nexavar (sorafenib). In addition, the response rate was 41% with Lenvima and 12% with Nexavar. The average overall survival was 13.6 months with Lenvima and 12.3 months with Nexavar.

The most common side effects with Lenvima in the study were similar to side effects reported in other studies.

Recommended For You
FDA NewsLeukemiaNewsworthy
Tibsovo First Drug Approved by the FDA for AML with IDH1 Mutation
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
Last modified: October 27, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country